Cargando…

The effect of casirivimab with imdevimab on disease progression in nonsevere COVID‐19 patients in a single hospital in Japan

BACKGROUND: Recent randomized trials have revealed that neutralizing monoclonal antibodies can reduce disease progression in mild–moderate COVID‐19 patients. However, no studies have investigated the effect of neutralizing monoclonal antibodies on clinical outcomes in Japan. METHODS: A single‐center...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komagamine, Junpei, Yabuki, Taku, Yoshihara, Satsuki, Tanaka, Nao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062551/ https://www.ncbi.nlm.nih.gov/pubmed/35509339 http://dx.doi.org/10.1002/jgf2.516

Ejemplares similares

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022)

Evaluation of Antimicrobial Drug Use and Concurrent Infections During Hospitalization of Patients With COVID-19 in Japan
por: Komagamine, Junpei, et al.
Publicado: (2022)

Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021)

Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022)

Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
por: Osugi, Yasuhiro, et al.
Publicado: (2022)

Casirivimab - Imdevimab in Covid 19 – Early Indian experience
por: Venkitakrishnan, Rajesh, et al.
Publicado: (2022)

Incidence of thromboembolic complications in hospitalized COVID-19 patients in a medical ward in Japan: A single-center retrospective and prospective observational study
por: Komagamine, Junpei, et al.
Publicado: (2022)

Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)

Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022)

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
por: Moriello, Nicola Schiano, et al.
Publicado: (2023)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
Publicado: (2022)

PROLONGED COVID-19 INFECTION IN AN IMMUNOSUPPRESSED PATIENT TREATED WITH CASIRIVIMAB/IMDEVIMAB
por: TOOR, SUBHAN A, et al.
Publicado: (2022)

Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19
por: Markovitz, Netana H., et al.
Publicado: (2022)

Casirivimab/imdevimab: Various toxicities: 2 case reports
Publicado: (2022)

Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19
por: Zitek, Tony, et al.
Publicado: (2022)

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
por: Hegazy, Sahar K., et al.
Publicado: (2023)

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
por: Falcone, Marco, et al.
Publicado: (2021)

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients
por: Hegazy, Sahar K., et al.
Publicado: (2023)

Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
por: Phan, Alexander T, et al.
Publicado: (2021)

French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)

A trend in prevalence of antimicrobial use and appropriateness of antimicrobial therapy in an acute care hospital from 2018 to 2019: repeated prevalence surveys in Japan
por: Komagamine, Junpei, et al.
Publicado: (2019)

Initial symptoms of patients with coronavirus disease 2019 in Japan: A descriptive study
por: Komagamine, Junpei, et al.
Publicado: (2020)

Retraction to “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
por: Hegazy, Sahar K., et al.
Publicado: (2023)

LB4. Casirivimab and Imdevimab for Treatment of Hospitalized Patients With COVID-19 Receiving Low Flow or No Supplemental Oxygen
por: Mylonakis, Eleftherios, et al.
Publicado: (2021)

Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
por: Isa, Flonza, et al.
Publicado: (2022)

Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19
por: Ruggeri, Matteo, et al.
Publicado: (2023)

Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan
por: Terakawa, Kanako, et al.
Publicado: (2022)

Association between potentially inappropriate medications at discharge and unplanned readmissions among hospitalised elderly patients at a single centre in Japan: a prospective observational study
por: Komagamine, Junpei, et al.
Publicado: (2019)

Full-text publication rate of abstracts presented at the Japan Primary Care Association Annual Meetings (2010–2012): a retrospective observational study
por: Komagamine, Junpei, et al.
Publicado: (2018)

Dégradation respiratoire post Casirivimab/Imdevimab : fréquence et facteurs de risque
por: Gerber, V., et al.
Publicado: (2022)

Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
por: Singh, Gurdeep, et al.
Publicado: (2022)

A SEVERE ADVERSE DRUG REACTION (ADR) TO REGEN-COV (CASIRIVIMAB AND IMDEVIMAB)
por: Abou-Jaoude, E., et al.
Publicado: (2022)

Risk factors for progression to acute respiratory failure after casirivimab and imdevimab administration: A retrospective study
por: Ito, Noriaki, et al.
Publicado: (2022)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Prevalence of antimicrobial use and active healthcare-associated infections in acute care hospitals: a multicentre prevalence survey in Japan
por: Komagamine, Junpei, et al.
Publicado: (2019)

Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
por: McCreary, Erin K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b75vod7ttmspi9lnnjluv0klv6